JP2015524913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524913A5 JP2015524913A5 JP2015502383A JP2015502383A JP2015524913A5 JP 2015524913 A5 JP2015524913 A5 JP 2015524913A5 JP 2015502383 A JP2015502383 A JP 2015502383A JP 2015502383 A JP2015502383 A JP 2015502383A JP 2015524913 A5 JP2015524913 A5 JP 2015524913A5
- Authority
- JP
- Japan
- Prior art keywords
- sodium
- composition
- phospholipid
- mol
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 31
- 150000003904 phospholipids Chemical class 0.000 claims 20
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 239000004094 surface-active agent Substances 0.000 claims 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims 11
- 239000000194 fatty acid Substances 0.000 claims 11
- 229930195729 fatty acid Natural products 0.000 claims 11
- 150000004665 fatty acids Chemical class 0.000 claims 10
- 239000002609 medium Substances 0.000 claims 9
- 239000003833 bile salt Substances 0.000 claims 8
- 235000012000 cholesterol Nutrition 0.000 claims 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000011734 sodium Substances 0.000 claims 5
- 229910052708 sodium Inorganic materials 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 239000012736 aqueous medium Substances 0.000 claims 4
- 239000012530 fluid Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 229940093761 bile salts Drugs 0.000 claims 2
- 229960003964 deoxycholic acid Drugs 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical group [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims 2
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 claims 2
- VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 claims 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims 2
- 229940045946 sodium taurodeoxycholate Drugs 0.000 claims 2
- WDFRNBJHDMUMBL-OICFXQLMSA-M sodium;(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-OICFXQLMSA-M 0.000 claims 2
- WDFRNBJHDMUMBL-FUXQPCDDSA-M sodium;(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-FUXQPCDDSA-M 0.000 claims 2
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 claims 1
- 108010077895 Sarcosine Proteins 0.000 claims 1
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003899 bactericide agent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- -1 carbon fatty acid Chemical class 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 238000007922 dissolution test Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000000126 in silico method Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 238000011160 research Methods 0.000 claims 1
- 238000004088 simulation Methods 0.000 claims 1
- AAYACJGHNRIFCT-YRJJIGPTSA-M sodium glycochenodeoxycholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)CC1 AAYACJGHNRIFCT-YRJJIGPTSA-M 0.000 claims 1
- IYPNVUSIMGAJFC-HLEJRKHJSA-M sodium;2-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)CC1 IYPNVUSIMGAJFC-HLEJRKHJSA-M 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162548.7 | 2012-03-30 | ||
| EP12162548.7A EP2645099A1 (en) | 2012-03-30 | 2012-03-30 | Biorelevant compositions |
| PCT/EP2013/056945 WO2013144374A1 (en) | 2012-03-30 | 2013-04-02 | Biorelevant compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524913A JP2015524913A (ja) | 2015-08-27 |
| JP2015524913A5 true JP2015524913A5 (https=) | 2016-06-02 |
| JP6348480B2 JP6348480B2 (ja) | 2018-06-27 |
Family
ID=48143258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015502383A Expired - Fee Related JP6348480B2 (ja) | 2012-03-30 | 2013-04-02 | 生体関連組成物（ＢｉｏｒｅｌｅｖａｎｔＣｏｍｐｏｓｉｔｉｏｎｓ） |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150064794A1 (https=) |
| EP (2) | EP2645099A1 (https=) |
| JP (1) | JP6348480B2 (https=) |
| KR (1) | KR20140144255A (https=) |
| CN (1) | CN104582689A (https=) |
| BR (1) | BR112014024256A8 (https=) |
| CA (1) | CA2867638A1 (https=) |
| IN (1) | IN2014DN07927A (https=) |
| MX (1) | MX357927B (https=) |
| NZ (1) | NZ700064A (https=) |
| WO (1) | WO2013144374A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011375432B2 (en) * | 2011-08-23 | 2016-02-04 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
| WO2019199238A1 (en) * | 2018-04-09 | 2019-10-17 | Vet Products Research And Innovation Center Company Limited | Inorganic mineral entrapped in nanoparticle production method thereof |
| GB201809627D0 (en) * | 2018-06-12 | 2018-07-25 | Biorelevant Com Ltd | Methods for preparing buffer solutions suitable for in vitro drug dissolution testing, drug solubility testing and/or drug profiling |
| GB201904757D0 (en) * | 2019-04-04 | 2019-05-22 | Biorelevant Com Ltd | Biorelevant composition |
| US20220373446A1 (en) * | 2019-06-28 | 2022-11-24 | Janssen Pharmaceutica Nv | Biorelevant dissolution media |
| US20230100584A1 (en) | 2020-02-19 | 2023-03-30 | Bayer Aktiengesellschaft | Predicting formulation properties |
| GB202112975D0 (en) | 2021-09-10 | 2021-10-27 | Biorelevant Com Ltd | Biorelevant dissolution compositions with reproducible spectral profiles |
| GB202405714D0 (en) * | 2024-04-23 | 2024-06-05 | Biorelevant Com Ltd | Biorelevant compositions and media for in vitro testing |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874795A (en) * | 1985-04-02 | 1989-10-17 | Yesair David W | Composition for delivery of orally administered drugs and other substances |
| GB8909022D0 (en) * | 1989-04-20 | 1989-06-07 | Cortecs Ltd | Pharmaceutical compositions |
| US6040188A (en) * | 1997-11-18 | 2000-03-21 | The Regents Of The University Of California | In vitro gastrointestinal mimetic protocol for measuring bioavailable contaminants |
| IT1296914B1 (it) * | 1997-12-01 | 1999-08-03 | Maria Rosa Gasco | Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera |
| WO2003042392A1 (en) * | 2001-11-15 | 2003-05-22 | Phares Pharmaceutical Research N.V. | Standardised phospholipid mixtures |
| EP1734937A1 (en) * | 2004-03-26 | 2006-12-27 | Cell Therapeutics Europe S.R.L. | Nanoparticle formulations of platinum compounds |
| GB0522942D0 (en) | 2005-11-10 | 2005-12-21 | Leigh Steven | Dissolution composition |
| PL1981516T3 (pl) * | 2006-01-27 | 2019-03-29 | Dupont Nutrition Biosciences Aps | Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom |
| WO2008040799A2 (en) | 2006-10-06 | 2008-04-10 | Boehringer Ingelheim International Gmbh | Process for preparing instant forms of aqueous mixed micellar solutions as physiological buffer systems for use in the analysis of in vitro release |
-
2012
- 2012-03-30 EP EP12162548.7A patent/EP2645099A1/en not_active Ceased
-
2013
- 2013-04-02 MX MX2014011789A patent/MX357927B/es active IP Right Grant
- 2013-04-02 CA CA2867638A patent/CA2867638A1/en not_active Abandoned
- 2013-04-02 WO PCT/EP2013/056945 patent/WO2013144374A1/en not_active Ceased
- 2013-04-02 BR BR112014024256A patent/BR112014024256A8/pt not_active Application Discontinuation
- 2013-04-02 NZ NZ700064A patent/NZ700064A/en not_active IP Right Cessation
- 2013-04-02 KR KR1020147030491A patent/KR20140144255A/ko not_active Ceased
- 2013-04-02 IN IN7927DEN2014 patent/IN2014DN07927A/en unknown
- 2013-04-02 EP EP13717734.1A patent/EP2830592A1/en not_active Withdrawn
- 2013-04-02 CN CN201380018498.8A patent/CN104582689A/zh active Pending
- 2013-04-02 JP JP2015502383A patent/JP6348480B2/ja not_active Expired - Fee Related
- 2013-04-02 US US14/389,701 patent/US20150064794A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524913A5 (https=) | ||
| Yoon et al. | Correlating membrane morphological responses with micellar aggregation behavior of capric acid and monocaprin | |
| Wang et al. | Studies on the sorption of tetracycline onto clays and marine sediment from seawater | |
| JP6348480B2 (ja) | 生体関連組成物（ＢｉｏｒｅｌｅｖａｎｔＣｏｍｐｏｓｉｔｉｏｎｓ） | |
| Perez-Moral et al. | Comparative study of the stability of multiple emulsions containing a gelled or aqueous internal phase | |
| Moghaddasi et al. | Soybean oil-based nanoemulsion systems in absence and presence of curcumin: Molecular dynamics simulation approach | |
| Maldonado-Valderrama et al. | Bile salts at the air–water interface: Adsorption and desorption | |
| Stachowicz‐Kuśnierz et al. | Modeling lung surfactant interactions with benzo [a] pyrene | |
| Zohairi et al. | Interaction of psychedelic tryptamine derivatives with a lipid bilayer | |
| BR112020008131A2 (pt) | composições aquosas compreendendo dicamba e um agente de controle de deriva embutido | |
| Heylings et al. | Identification of an alginate-based formulation of paraquat to reduce the exposure of the herbicide following oral ingestion | |
| Lee et al. | Permeability of model stratum corneum lipid membrane measured using quartz crystal microbalance | |
| PT1952142E (pt) | Composição de dissolução para examinar a solubilidade de fármacos | |
| CN114573832A (zh) | 一种壳聚糖盐酸盐稳定的高内相乳液及其制备方法和应用 | |
| Li et al. | Antibacterial mechanism of hydrophobic deep eutectic solvents-in-water nanoemulsion: Experimental and molecular dynamic simulation studies | |
| CN204988977U (zh) | 一种盐雾试验箱 | |
| Kataoka et al. | Salinity‐dependent toxicity of water‐dispersible, single‐walled carbon nanotubes to Japanese medaka embryos | |
| Xin et al. | Effects of sodium halide on the interaction between polyvinylpyrrolidone and sodium oleate: surface tension and oscillating barrier studies | |
| Markina et al. | Self-assembly of micelles in organic solutions of lecithin and bile salt: Mesoscale computer simulation | |
| Zhu et al. | Rough glass surface-mediated formation of vesicles from lauryl sulfobetaine micellar solutions | |
| CA3135974A1 (en) | Biorelevant composition | |
| Najar et al. | Mixed micellization and mixed monolayer formation of sodium cholate and sodium deoxycholate in presence of hydrophobic salts under physiological conditions | |
| Li et al. | Adsorption and bioaccessibility of phenanthrene on carbon nanotubes in the in vitro gastrointestinal system | |
| Helgason et al. | Examination of the interaction of chitosan and oil-in-water emulsions under conditions simulating the digestive system using confocal microscopy | |
| Lee et al. | Irremovable Blood Stain in Lung: Air-to-Interface Transport of Albumin and Its Mechanical Response to Biaxial Compression/Expansion |